Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

NCT05208307 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Plasma Cell Myeloma

Interventions

BIOLOGICAL: Belantamab Mafodotin
DRUG: Dexamethasone
DRUG: Pomalidomide

Sponsor

Emory University

Collaborators

[object Object]
[object Object]